HUE026660T2 - Ibandronát többlépéses szintézise - Google Patents
Ibandronát többlépéses szintézise Download PDFInfo
- Publication number
- HUE026660T2 HUE026660T2 HUE08718377A HUE08718377A HUE026660T2 HU E026660 T2 HUE026660 T2 HU E026660T2 HU E08718377 A HUE08718377 A HU E08718377A HU E08718377 A HUE08718377 A HU E08718377A HU E026660 T2 HUE026660 T2 HU E026660T2
- Authority
- HU
- Hungary
- Prior art keywords
- methyl
- pentyl
- carried out
- formula
- pentylamine
- Prior art date
Links
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 title description 7
- 229940015872 ibandronate Drugs 0.000 title description 7
- 238000007040 multi-step synthesis reaction Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 34
- UOIWOHLIGKIYFE-UHFFFAOYSA-N n-methylpentan-1-amine Chemical compound CCCCCNC UOIWOHLIGKIYFE-UHFFFAOYSA-N 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 17
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000007062 hydrolysis Effects 0.000 claims description 12
- 238000006460 hydrolysis reaction Methods 0.000 claims description 12
- 238000010533 azeotropic distillation Methods 0.000 claims description 10
- 230000005494 condensation Effects 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 238000009833 condensation Methods 0.000 claims description 8
- -1 salt salt Chemical class 0.000 claims description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000012022 methylating agents Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- IUPJSFOHUQGEDR-UHFFFAOYSA-N 1,3-dioxetanedione Chemical compound O=C1OC(=O)O1 IUPJSFOHUQGEDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 230000004888 barrier function Effects 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 150000004682 monohydrates Chemical class 0.000 description 16
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 15
- YWSCUVIPKSJBRU-UHFFFAOYSA-N 3-[methyl(pentyl)azaniumyl]propanoate Chemical compound CCCCCN(C)CCC(O)=O YWSCUVIPKSJBRU-UHFFFAOYSA-N 0.000 description 14
- ZWKFEVVFVAGPDE-UHFFFAOYSA-N methyl 3-[methyl(pentyl)amino]propanoate Chemical compound CCCCCN(C)CCC(=O)OC ZWKFEVVFVAGPDE-UHFFFAOYSA-N 0.000 description 14
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- NNTVKFAXDYRERB-UHFFFAOYSA-N n-pentyl-1-phenylmethanimine Chemical compound CCCCCN=CC1=CC=CC=C1 NNTVKFAXDYRERB-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- DRPKUPBGKFMTRM-UHFFFAOYSA-N (2-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid Chemical compound CC(N)C(O)(P(O)(O)=O)P(O)(O)=O DRPKUPBGKFMTRM-UHFFFAOYSA-N 0.000 description 9
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 9
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000004821 distillation Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229940000635 beta-alanine Drugs 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WIWGXURDMPANAJ-UHFFFAOYSA-N Mono-Natrium-Salz Natural products S1C=C(COC(N)=O)C(C(O)=O)N2C(=O)C(OC)(NC(=O)CCCC(N)C(O)=O)C21 WIWGXURDMPANAJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 208000015202 calcium metabolic disease Diseases 0.000 description 1
- 238000003926 complexometric titration Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (3)
- EP 2 144 919 lajstromszámó európai szabadalom Igénypontjainak fordítása: 1,Eprâs ! képletöI 3~(N-metÍl44~pentii)aminO'1--hidroxrpropán-1)1'dsfoszfonsav~mononálrit3nisö··' monohidiii előállítására, az említett eljárás során: Nl-maííit^-tSífentíl-p-aiaíirn-f^^tíl-észtert bsdroiszáfunk IV képletö:IV :N~mGHi-N-penüi-fMaÄ előállítására, dí#MkaffconátéÍ adunk hozzá, azeotrop desztiéolét végzünk a maradék víz eltávolítására, és ezt kővetően a IV képletö vegyüieíeí foszfonPklonddal és foszforossawal bíszfoszforilezzük, és előállítjuk a m ononátnumso-monohldrátát. 2x Eljárás I képlett!I 3V^'níetíl4^~pentil)anilne-1“hldroxlpropán~1,1 -dlfoszfonsav-mononátrsu msó~ monohidrát előállítására, az említett eljárás sárim (a) N-penölamint kondenzálunk benzaldeWddeí II képletöII Ndmnzidin-N-penlliiíIn élőállításiri, (b) az N-benzlIldén-N-pentlIamlnt N-metíl-N-pentiíamlnná alakítjuk metilezöszerrel, |el az N^metihN^pentiamlnt meiMkrlIáttal III kipletiIfi iN-meli-N-penfi-p-alafïio-rTieîil-èsztefré alakítjuk, (d) az N-melíl-N-penil-p-alanlü-mell-észtert Ndrollzäljuk IV képleteív Ni-raeíil-N-'penii-p-alaríia előállítására, dieil-karbonátoi c^dunk hozzá, azeotrop desztláelót végzőnk a maradék víz eltávolítására, fe) a IV képlete vegyüJefet foszforil-kiorlddai és foszforossawal biszioszfeníezzük, és előállítjuk a mohonátfiurrisó~monohldráiot, 3. A 2. igénypont szedni eljárás, azzal jellemezve, hogy az a) lépésben a kondenzációt megfelelő oldószerben, 40 T— 90 X- hőmérsékleten végezzük. 4. A 2. vagy 3, igénypont szerinti e§áris, azzal jellemezve, hogy a b) lépésben az átalakítás! 80 °C - 110 X hőmérsékleten végezzük. 5. A 2-4. Igénypont szerinti eljárás, azzal jellemezve, hogy a b) lépésben az átalakítást metitezöszerként dtmetll-szulfattai végezzük. 6. A 2-5.. Igénypont szerinti lejárás, azzal: jellemezve, hogy a c) lépésben az átalakítást rnegíelelé oldószerben, 10 - 65 °C reakoióhőmérséklefen végezzek, T. Az 1-8. Igénypontok szerinti eljárás, azzal jellemezve, hogy a hidrolízist vízben, 98 °C --- 100 ftC hőmérsékleten végezzük.
- 3. Az 1-8. igénypontok szerinti eljárás, azzal jellemezve, hogy a hidrolízist híg ásványi savban végezzük. δ. Âz 1-8. igénypontok szerinti éprás, azzal jellemezve, hogy az e) tépésben a hiszfosÄriiezashoz: aZ; !N"metit~N-peoiiHi~alantnÄsztöni;~klorii^bszforö:Ssa¥ móiarányt az 1,0:3,0:3,0 - 1,0:1,4:2,410101 választjuk, m igénypontok szerinti eljárás, azzal pttemezve, hogy az e) lépésben a biszfbszfenlezéshaz a reakcíohőmÉmékistet 00 °0 ~ 100 °C közöl választjuk.
- 11. Az ι-ίο. igénypontok szerinti leprás, azzal jellemezve, hogy a niononátriumsó-rnonohlirát Mipzi8ését azzal válljyk ki, hogy a vizes reakcióetegy pH-ját 3,5 és 6,0 közötti értékre állítjuk be vizes n#rlum#MroMd--oMata!.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105915 | 2007-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE026660T2 true HUE026660T2 (hu) | 2016-07-28 |
Family
ID=39722497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08718377A HUE026660T2 (hu) | 2007-04-11 | 2008-04-01 | Ibandronát többlépéses szintézise |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7662990B2 (hu) |
| EP (1) | EP2144919B1 (hu) |
| JP (1) | JP5220843B2 (hu) |
| KR (1) | KR101150662B1 (hu) |
| CN (1) | CN101679465B (hu) |
| AU (1) | AU2008238058B2 (hu) |
| BR (1) | BRPI0809548A8 (hu) |
| CA (1) | CA2683971C (hu) |
| DK (1) | DK2144919T3 (hu) |
| ES (1) | ES2558383T3 (hu) |
| HU (1) | HUE026660T2 (hu) |
| IL (1) | IL201307A (hu) |
| MX (1) | MX2009010850A (hu) |
| PL (1) | PL2144919T3 (hu) |
| SI (1) | SI2144919T1 (hu) |
| WO (1) | WO2008125483A2 (hu) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316840A1 (en) * | 2007-04-19 | 2011-05-04 | Dr. Reddy's Laboratories Limited | Ibandronate Sodium Polymorphs |
| WO2011016738A1 (en) * | 2009-08-05 | 2011-02-10 | Zaklady Farmaceutyczne Polpharma Sa | A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate |
| CN101863919B (zh) * | 2010-07-05 | 2011-11-23 | 武汉同源药业有限公司 | 一种化合物伊班膦酸钠的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919321A (en) * | 1966-11-08 | 1975-11-11 | Hoffmann La Roche | Halo-substituted-5H-dibenzo{8 a,d{9 cyclohepten-5-ones |
| DE2534391C2 (de) * | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren |
| US4220611A (en) * | 1978-06-29 | 1980-09-02 | Sandoz, Inc. | Polyoxyalkylene bridged phosphate esters |
| DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| DE3808074A1 (de) * | 1988-03-11 | 1989-09-21 | Henkel Kgaa | Verfahren zur herstellung von azacycloalkan-2,2-diphosphonsaeuren |
| DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| PE20011065A1 (es) | 2000-02-01 | 2001-11-21 | Procter & Gamble | Proceso para fabricar bisfosfonatos geminales |
| WO2003097655A1 (en) * | 2002-05-17 | 2003-11-27 | Teva Pharmaceutical Industries Ltd. | Use of certain diluents for making bisphosphonic acids |
| PT1656386E (pt) * | 2003-08-21 | 2010-03-05 | Sun Pharmaceuticals Ind Ltd | Processo para a preparação de compostos de ácido bifosfónico |
| DE602004032577D1 (de) * | 2003-12-23 | 2011-06-16 | Alchymars S P A | Amorphe Form das Natriumsalzes der Ibandronsäure |
| MX2007000087A (es) * | 2004-06-23 | 2007-11-06 | Teva Pharma | Acido ibandronico solido y cristalino. |
| DE602005025977D1 (de) | 2004-08-23 | 2011-03-03 | Teva Pharma | Kristalline form des ibandronat-natriums und herstellungsverfahren dafür |
| US7214818B2 (en) * | 2004-10-29 | 2007-05-08 | Hoffmann-La Roche Inc. | Method for synthesizing bisphosphonate |
| EP2363401A1 (en) * | 2005-02-01 | 2011-09-07 | F. Hoffmann-La Roche AG | Ibandronate polymorph B |
| HUE042316T2 (hu) * | 2005-02-01 | 2019-06-28 | Atnahs Pharma Uk Ltd | Az Ibandronát A polimorf orvosi alkalmazása |
| WO2007013097A1 (en) * | 2005-07-25 | 2007-02-01 | Natco Pharma Limited | Improved process for the preparation of ibandronate sodium |
-
2008
- 2008-04-01 EP EP08718377.8A patent/EP2144919B1/en not_active Not-in-force
- 2008-04-01 SI SI200831566T patent/SI2144919T1/sl unknown
- 2008-04-01 DK DK08718377.8T patent/DK2144919T3/en active
- 2008-04-01 HU HUE08718377A patent/HUE026660T2/hu unknown
- 2008-04-01 MX MX2009010850A patent/MX2009010850A/es active IP Right Grant
- 2008-04-01 CA CA2683971A patent/CA2683971C/en not_active Expired - Fee Related
- 2008-04-01 JP JP2010502488A patent/JP5220843B2/ja active Active
- 2008-04-01 ES ES08718377.8T patent/ES2558383T3/es active Active
- 2008-04-01 CN CN200880011546XA patent/CN101679465B/zh not_active Expired - Fee Related
- 2008-04-01 US US12/060,314 patent/US7662990B2/en active Active
- 2008-04-01 BR BRPI0809548A patent/BRPI0809548A8/pt not_active IP Right Cessation
- 2008-04-01 AU AU2008238058A patent/AU2008238058B2/en not_active Ceased
- 2008-04-01 KR KR1020097023419A patent/KR101150662B1/ko not_active IP Right Cessation
- 2008-04-01 PL PL08718377T patent/PL2144919T3/pl unknown
- 2008-04-01 WO PCT/EP2008/053876 patent/WO2008125483A2/en active Search and Examination
-
2009
- 2009-10-01 IL IL201307A patent/IL201307A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0809548A2 (pt) | 2014-09-16 |
| KR101150662B1 (ko) | 2012-05-29 |
| AU2008238058A1 (en) | 2008-10-23 |
| US20080255386A1 (en) | 2008-10-16 |
| AU2008238058B2 (en) | 2010-12-02 |
| EP2144919B1 (en) | 2015-12-02 |
| JP5220843B2 (ja) | 2013-06-26 |
| ES2558383T3 (es) | 2016-02-03 |
| BRPI0809548A8 (pt) | 2018-10-16 |
| KR20090130117A (ko) | 2009-12-17 |
| WO2008125483A3 (en) | 2008-12-18 |
| SI2144919T1 (sl) | 2016-02-29 |
| PL2144919T3 (pl) | 2016-05-31 |
| IL201307A0 (en) | 2010-05-31 |
| DK2144919T3 (en) | 2015-12-14 |
| EP2144919A2 (en) | 2010-01-20 |
| CA2683971A1 (en) | 2008-10-23 |
| CN101679465B (zh) | 2013-08-21 |
| WO2008125483A2 (en) | 2008-10-23 |
| JP2010523614A (ja) | 2010-07-15 |
| US7662990B2 (en) | 2010-02-16 |
| IL201307A (en) | 2013-10-31 |
| CN101679465A (zh) | 2010-03-24 |
| CA2683971C (en) | 2013-02-26 |
| MX2009010850A (es) | 2009-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2585027C (en) | Process for the preparation of bisphosphonates | |
| US20090281320A1 (en) | Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof | |
| HUE026660T2 (hu) | Ibandronát többlépéses szintézise | |
| FI91873B (fi) | Menetelmä 2-fosfonobutaani-1,2,4-trikarboksyylihapon ja sen alkalimetallisuolojen valmistamiseksi jatkuvatoimisesti | |
| US20120022282A1 (en) | Process for the preparation of 2,4,6-octatriene-1-oic acid and 2,4,6-octatriene-1-ol | |
| US7485726B2 (en) | Process for the preparation of risedronate sodium hemi-pentahydrate | |
| US8076483B2 (en) | Process for the preparation of pure risedronic acid or salts | |
| EP1803727B1 (en) | Improved process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts | |
| JPH05222071A (ja) | アミノアルカンホスホン酸、その塩及び／またはエステルの製造方法 | |
| JP2008538556A (ja) | ヒドロキシル化イソフラボンの製造方法 |